Related by context. All words. (Click for frequent words.) 67 Zometa hazard 67 8mg/kg 66 XIENCE V vs. 66 plus methotrexate 66 dapagliflozin plus 65 placebo fluoxetine 65 -#.# mg dL [001] 65 belimumab 65 prednisone prednisolone plus 64 infliximab monotherapy 64 FOLFIRI alone 64 TAXUS p value 64 oxycodone CR 64 mg TID 63 plus OBT 63 tolterodine ER 63 lopinavir r arm 63 achieved ACR# 63 ACTEMRA TM 63 placebo p = 63 Flu Cy 63 plus dexamethasone 63 stage IIIb IV 62 mcg QD 62 adjunctive placebo 62 SLE Responder Index 62 mcg BID 62 discontinuations due 62 ACR# response 62 plus prednisone prednisolone 62 REMICADE monotherapy 62 plus MTX 62 -#.# mg dL [002] 61 #mg BID [001] 61 Treatment Naive Patients 61 FOLFOX4 alone 61 mg ustekinumab 61 certolizumab 61 receiving golimumab 61 -#.# log# 61 plus glimepiride 61 mg QD 61 lumbar spine BMD 61 serologically active patients 61 #.#mg/dL 61 titrated glipizide plus 61 placebo p 60 linaclotide treated 60 alfa 2a 60 peginterferon alfa 2a 60 HBeAg negative patients 60 plus prednisone 60 generalized edema 60 mcg kg REBETOL 60 oxycodone IR 60 p = NS 60 4mg/kg 60 lopinavir r 60 ALVESCO 60 mcg albinterferon alfa 2b 60 budesonide pMDI 60 non splenectomized 60 FOLFOX4 60 placebo dexamethasone 59 mcg Albuferon 59 adjunctive ABILIFY 59 moderate renal impairment 59 plus COPEGUS 59 log# IU mL 59 CIMZIA TM 59 Pegasys ® 59 Oral Fingolimod 59 certolizumab pegol 59 SELENA SLEDAI score 59 Montgomery Asberg Depression 59 FluCAM arm 59 VELCADE melphalan 59 ACR# responses 59 serologically active SLE 59 echinacea tablets 59 mg BID dose 59 severe exacerbations 59 PREZISTA r 59 HBeAg seroconversion 59 interferon alfa 2a 59 receiving ISENTRESS 59 splenectomized 58 Engerix B 58 Folfox 58 CIMZIA TM certolizumab pegol 58 nicardipine 58 urate lowering therapy 58 tapentadol ER 58 Psoriasis Area 58 REYATAZ r arm 58 Relapsing Multiple Sclerosis 58 clodronate 58 mitoxantrone plus 58 mg + GLY 58 febrile neutropenia 58 plus ribavirin 58 dose cytarabine 58 pegylated interferon alpha 58 seropositive patients 58 #mg/day [002] 58 PREZISTA r arm 58 mg qd 58 morphometric vertebral fractures 58 severe neutropenia 58 plus GP IIb 58 adalimumab 58 receiving highly emetogenic 58 REYATAZ r 58 ACR# ACR# 58 TEAEs 58 Index CDAI 58 CR nPR 58 comparator arm 58 adefovir treated 58 FluCAM 58 confidence interval #.#-#.# 58 adalimumab Humira 57 receiving prophylactic anticoagulation 57 bleeding pallor 57 Peg IFN 57 ARCALYST ® 57 relapsed MM 57 mg BID 57 BARACLUDE ® 57 Lucentis monotherapy 57 sustained virological response 57 sustained virologic response 57 #mg BID [003] 57 amoxicillin clavulanate 57 -#.# log# copies mL 57 binary restenosis 57 Newly Diagnosed Patients 57 mg Lucentis 57 annualized relapse 57 interferon alfa 57 MADRS score 57 bortezomib refractory 57 #mg/day [001] 57 plus aztreonam 57 Lupuzor ™ 57 thrombosis embolism 57 CrCl 57 dalteparin 57 mg/m2 IV 57 deep venous thromboses 57 recurrent glioblastoma multiforme 57 Patients Receiving 57 Doxil ® 57 primary hypercholesterolemia 57 receiving VICTRELIS 57 Median progression 57 Median PFS 57 CCyR 57 fasting plasma glucose FPG 57 Pegasys plus Copegus 57 Rating Scale MADRS 57 weekly CSBMs 57 tapentadol IR 57 GOUT 57 peripheral edema 57 ribavirin RBV 57 FOLFIRI 57 Free Survival PFS 57 nondiabetic patients 57 CIMZIA ™ 57 ALIMTA cisplatin 57 #.#/#.# mmHg [001] 57 incidence ≥ 56 ritonavir boosted 56 humanized interleukin 6 56 sUA 56 #mg QD [001] 56 Viread Emtriva Sustiva 56 YMRS 56 #.# #.# -#.# [001] 56 low dose Iluvien 56 FOLFOX 56 Score TOS 56 Randomized Double Blind 56 Mg Uk 56 biochemical relapse 56 ritonavir boosted atazanavir 56 abacavir lamivudine 56 Ishak fibrosis score 56 achieved statistical significance 56 achieved CCyR 56 GERD symptom 56 serum phosphorous 56 pegylated interferon alfa 2b 56 CYP#A# substrate 56 NATRECOR R 56 subcutaneous enoxaparin 56 5-FU/LV 56 PRADAXA #mg 56 mcg linaclotide 56 p = #.# [004] 56 microgram kg 56 HBeAg positive patients 56 Adefovir 56 x ULN 56 venlafaxine XR 56 hypophosphatemia 56 invasive aspergillosis 56 saline placebo 56 R# #mg BID 56 Erythropoietic therapies may 56 mg simvastatin 56 plus gemcitabine 56 aldosterone antagonist 56 virologic response 56 PREZISTA ritonavir 56 adriamycin 56 Scale EDSS 56 aspirin heparin 56 % CI #.#-#.# [003] 56 #mg QD [002] 56 Castration Resistant Prostate Cancer 56 FOLFOX6 56 MCyR 56 laboratory abnormalities 56 nonsignificant difference 56 5 Fluorouracil 56 rimonabant #mg/day 56 undetectable virus HCV 56 oral allopurinol 56 placebo PBO 56 doxazosin 56 mild renal insufficiency 56 lispro 56 unfractionated heparin UFH 56 glycated hemoglobin levels 56 baseline A1C 55 rimonabant #mg 55 PASI scores 55 BARACLUDE r 55 receiving CIMZIA #mg 55 docetaxel chemotherapy 55 P = .# 55 sirolimus stent 55 hemoglobin A1c levels 55 Pred Forte 55 % CI #.#-#.# [007] 55 acute gout flares 55 plus glycoprotein IIb 55 nadroparin 55 chlorambucil 55 3mg/kg 55 ULORIC 55 desvenlafaxine succinate 55 confidence interval CI 55 fluticasone salmeterol 55 Raptiva r 55 confirmed CCyR 55 Pegasys peginterferon alfa 2a 55 RECIST Response Evaluation Criteria 55 Peginterferon Alfa 2a 55 Meets Primary Endpoint 55 Median survival 55 peginterferon alfa 2b 55 KRAS mutant tumors 55 ALT normalization 55 pegylated interferon alfa 55 doxorubicin cyclophosphamide 55 mg kg dose 55 rosuvastatin #mg 55 metformin IR 55 active ankylosing spondylitis 55 APTIVUS r 55 headache nasopharyngitis 55 fatigue asthenia 55 Viread Emtriva SUSTIVA 55 arterial thromboembolic events 55 RGT arm 55 μg doses 55 NPH insulin 55 HBeAg negative 55 chemoradiation therapy 55 complete cytogenetic response 55 HAQ DI 55 DAS# scores 55 #mg/m# [002] 55 ug kg 55 Fasting blood glucose 55 baseline HbA1c 55 antiretroviral naïve 55 CR CRu 54 PANSS total 54 severe hypoglycemic 54 CI -#.# 54 salmeterol fluticasone 54 HbA 1c levels 54 refractory ischemia 54 Sustained virologic response 54 tamoxifen Nolvadex ® 54 achieved PASI 54 achieving sustained virologic 54 mcg doses 54 advanced hepatocellular carcinoma 54 elevated ALT 54 microbiological eradication 54 gout flares 54 glimepiride 54 interferon ribavirin 54 IPSS 54 dizziness nausea diarrhea 54 oral diclofenac 54 SVR# 54 Delivery Starts 54 tirofiban 54 zolmitriptan 54 treatment naive genotype 54 ug dose 54 Taxus Stent 54 PEGylated anti 54 progression TTP 54 COMBIVIR 54 oral antidiabetic medication 54 gp# vaccine 54 definite stent thrombosis 54 weekly subcutaneous injections 54 Expanded Disability Status 54 EGRIFTA TM tesamorelin 54 KRAS mutations occur 54 interferon alfa 2b 54 BEACOPP 54 fluorouracil 54 TAXUS Express Stent 54 overt nephropathy 54 Physical Function 54 SSRI SNRI 54 adefovir 54 mg/# hr 54 Q2W 54 ALT elevation 54 Demonstrate Significant 54 daunorubicin 54 ACR# [002] 54 pegylated interferon alfa 2a 54 log# copies mL 54 IIIa inhibitors 54 Bronchopulmonary Dysplasia 54 Morning Sentence Fragments 54 CDAI score 54 vincristine doxorubicin 54 relapsed refractory multiple myeloma 54 SGPT 54 Pharmacokinetic parameters 54 ADCS CGIC 54 Secondary endpoints included 54 events AEs 54 XIENCE V PROMUS Stent 54 efavirenz EFV 54 atazanavir ritonavir 54 recurrent VTE 54 Vasomotor Symptoms 54 malignancy HCM 54 Hepatitis C Genotype 54 locoregional disease 54 methotrexate monotherapy 54 placebo 54 degarelix 54 NRTI sparing 54 NNT = 54 postmenopausal osteoporotic women 54 Operative mortality 54 daily Infergen 54 hypokalemia 54 moderate hepatic impairment 54 A1C levels 54 titrated glipizide 54 % Confidence Interval 54 FOLPI 53 LPV r 53 log# reduction 53 PSA nadir 53 Demonstrated Significant 53 FROVA 53 squamous histology 53 PegIFN RBV 53 HbA1c levels 53 seroprotection 53 leukemia AML 53 cytogenetic responses 53 relapsing multiple sclerosis 53 Livable Streets Events 53 mycophenolate mofetil 53 + PH# 53 azilsartan medoxomil 53 s# s# 53 primary generalized tonic 53 events TEAEs 53 β blocker 53 unstable angina UA 53 urinary N telopeptide 53 doripenem 53 carboplatin AUC 53 NSTEMI 53 Hazard Ratio HR 53 preintervention 53 octreotide LAR 53 Crohn Disease Activity 53 IFN alfa 53 cytogenetic response 53 ribavirin therapy 53 esophageal erosions 53 nadolol 53 mL/min/#.# m 2 53 achieved sustained virological 53 quetiapine risperidone 53 INFERGEN 53 administered cetrorelix 53 TNF Tumor Necrosis Factor 53 RLAI 53 hypomagnesemia 53 See CLINICAL PHARMACOLOGY 53 serum urate levels 53 ARCOXIA 53 Decompensated Heart Failure 53 dose colchicine 53 Timed Walk 53 plus octreotide LAR 53 Secondary endpoints include 53 CANCIDAS 53 elevated transaminases 53 TNF antagonists 53 IN CONFERENCE PLAY 53 Primary endpoints 53 Index CDAI score 53 free survival PFS 53 dacarbazine 53 racemic albuterol 53 neuropathy sensory 53 ATACAND 53 ACE Inhibitors 53 salmeterol fluticasone propionate 53 CIPN 53 steroid dexamethasone 53 dosed intravenously 53 nonvertebral fractures 53 Severity Index PASI 53 lispro alone 53 Cyclophosphamide 53 J Antimicrob Chemother 53 detectable HCV RNA 53 â ‰ ¥ 53 mcg mL 53 BPRS PSS 53 leukopenia 53 via intradermal injections 53 decitabine 53 #mg #mg #mg [003] 53 Non inferiority 53 insulin detemir 53 Double Blind Randomized 53 experienced virologic failure 53 pegylated liposomal doxorubicin 53 HDRS 53 ps :# 53 systemic corticosteroid 53 MARINOL R 53 mCi kg 53 prospectively stratified 53 Annualized ROE 53 Lupuzor TM 53 Thal Dex 53 hematologic adverse 53 coinfected patients 53 q#h 53 CI #.#-#.# [002] 53 HbA1C levels 53 EGRIFTA ™ tesamorelin 53 IBDQ 53 Shows Efficacy 53 aminotransferases 53 arthralgia 53 events MACE 53 % CI #.#-#.# [006] 53 IFL chemotherapy regimen 53 ABC/3TC 53 Severe Asthma 52 null responders 52 rapid virologic response 52 Bone Metastases 52 colesevelam HCl 52 mEq L 52 estramustine 52 TLUS 52 STELARA ® 52 nevirapine Viramune 52 oral rivaroxaban 52 #Gy 52 cell lymphoma CTCL 52 nasopharyngitis 52 rizatriptan 52 Montgomery Åsberg Depression 52 mucosal healing 52 Response Evaluation Criteria 52 Invasive Breast Cancer 52 HbA 1c 52 Community Acquired Pneumonia 52 pulmonary exacerbations 52 serum potassium 52 ADAS cog 52 low dose cytarabine 52 QTcF 52 hematologic toxicity 52 nmol l 52 median PFS 52 aspirin clopidogrel 52 bronchial hyperresponsiveness 52 ARIXTRA 52 alanine aminotransferase 52 urinary cortisol 52 mcg kg 52 TDF FTC 52 mL/min/#.# m2 52 Solid Tumors 52 gout flare 52 paricalcitol 52 leucopenia 52 pegIFN 52 alanine aminotransferase ALT 52 ATV RTV 52 oral vancomycin 52 non squamous histology 52 Hazard Ratio 52 avosentan 52 Functional Outcomes 52 J Shoulder Elbow 52 acarbose 52 AVODART 52 beclomethasone dipropionate 52 HAM D# scores 52 % CI #.#-#.# [005] 52 nonfatal stroke 52 LEXIVA r 52 anemia hemoglobin 52 CYPHER Stent 52 mg m² 52 somatostatin analog 52 posaconazole 52 Ischaemic Stroke 52 p = .# [001] 52 pegaptanib 52 AVweb Question 52 Fludara 52 PEGylated Fab fragment 52 Unified Parkinson Disease 52 log# 52 hip BMD 52 treatment emergent adverse 52 Hb A1C 52 mild renal impairment 52 QD dosing 52 mg d 52 achieved sustained virologic 52 nonvertebral 52 Ann Oncol 52 pegylated IFN 52 undetectable HCV RNA 52 imipenem 52 peginterferon alfa 2a #KD 52 mg p = 52 minimally symptomatic 52 Perforomist Inhalation Solution 52 neutropaenia 52 biphasic insulin aspart 52 Nephrol Dial Transplant 52 DOXIL 52 mitoxantrone 52 protease inhibitor PI 52 serum urate 52 ALND 52 CHANGE WEEKLY CHANGE 52 mCRC patients 52 Rate ORR 52 BENICAR HCT 52 nasopharyngitis headache 52 Navelbine 52 tamsulosin 52 benazepril 52 Capacity FVC 52 reduce serum phosphate 52 dose clopidogrel 52 fibrinolysis 52 p = ns 52 TMC# r 52 Corticosteroid 52 μg dose 52 neurologic progression 52 baseline PASI 52 0 document.write 52 trough FEV1 52 target lesion revascularization 52 Teriflunomide 52 demonstrated clinically meaningful 52 noninferior 52 HDL Cholesterol 52 reinfarction 52 mso tstyle colband size 52 refractory NSCLC 52 Pharmacokinetics PK 52 FDA defined valvulopathy 52 aspartate aminotransferase 52 DAS# CRP 52 renal insufficiency 52 peginterferon 52 esophageal candidiasis 52 mean baseline A1C 52 Arch Intern Med 52 International Prostate Symptom 52 #.#g/day 52 Events MACE 52 docetaxel prednisone 52 mg kg Hematide 52 NFL Inactives 51 corticosteroid dose 51 tiotropium 51 serum phosphorus 51 Investigational Drug 51 mso tstyle rowband size 51 voriconazole 51 Clostridium difficile Infection 51 rFVIIa 51 piperacillin tazobactam 51 IU mL 51 IIIa inhibitor 51 PREZISTA rtv 51 mRCC 51 atorvastatin #mg 51 Scale EDSS score 51 HAM D# 51 REYATAZ ® 51 6R BH4 51 noncarriers 51 InsiderAsia Model Portfolio 51 serum phosphate 51 vaginal progesterone gel 51 #mg doses [002] 51 Hepatitis C Antiviral 51 DAS# remission 51 ACE inhibitor ramipril 51 glulisine 51 hepatitis C genotype 51 EURIDIS 51 clinically meaningful improvements 51 aldosterone antagonists 51 p = 51 highest tertile 51 pooled comparator 51 NATRECOR ® 51 nitroprusside 51 repeat paracentesis 51 lumbar spine bone 51 androgen suppression 51 ipsilateral stroke 51 Cimzia TM 51 CsA 51 azathioprine 51 metastatic CRC 51 #mg/kg [002] 51 zidovudine lamivudine 51 NMIBC 51 fasting triglyceride levels 51 virologic failure 51 irbesartan 51 peginterferon alpha 2a 51 IRLS 51 baminercept 51 Gene Mutation Linked 51 COZAAR 51 HCV Genotype 51 copies mL 51 sumatriptan naproxen sodium 51 azacitidine 51 p = #.# [002] 51 -#.# mm Hg 51 PANSS scores 51 splenectomized patients 51 endoscopic remission 51 atherothrombotic events 51 active comparator 51 ischemia driven 51 Y BOCS 51 sulfasalazine 51 serum HBV DNA 51 alemtuzumab treated 51 underwent liver transplantation 51 Jeremy Deutsch Kamloops 51 Ophena TM 51 flutamide 51 rituximab refractory 51 abdominal pain abdominal discomfort 51 tipranavir r 51 bosentan 51 perioperative complications 51 lamivudine monotherapy 51 CMV disease 51 hemoglobin A1c HbA1c 51 tenofovir emtricitabine 51 mm Stent 51 colorectal adenoma 51 glycosylated hemoglobin levels 51 Arch Facial Plast 51 HUMIRA achieved PASI 51 Pemetrexed 51 zonisamide SR 51 Left Ventricular Ejection Fraction 51 Nystatin current 51 Apidra ® 51 paliperidone ER 51 placebo Hazard Ratio 51 WinInfo Short Takes 51 % CI #.#-#.# [008] 51 IOP lowering 51 drotrecogin alfa activated 51 BMS p = 51 stage IIIB 51 idarubicin 51 transaminase elevations 51 IRLS score 51 darunavir r 51 XELOX 51 umol L 51 FFNS 51 nitazoxanide 51 Genes Predict 51 pegylated interferon alpha 2a 51 UACR 51 baseline FEV 51 cerebrovascular events 51 XIENCE V demonstrated 51 Natalizumab 51 crizotinib PF # 51 cEVR 51 ANN INTERN MED 51 HBeAg 51 complete cytogenetic 51 melphalan prednisone 51 VcMP 51 hypercalcemia 51 ritonavir boosted lopinavir 51 Solid Tumors criteria 51 solifenacin 51 Baseline characteristics 51 metastatic hormone refractory 51 amprenavir 51 PEG interferon 51 Severely Obese 51 liposome injection 51 DAPT 51 5FU 51 IM progesterone 51 symptomatic VTE 51 locoregional recurrence 51 EMEND 51 plasma HCV RNA 51 SELENA SLEDAI 51 perioperatively 50 oral antidiabetes 50 preoperative chemotherapy 50 nonmetastatic 50 intravenous bisphosphonates 50 achieve sustained virologic 50 tipranavir ritonavir 50 RECIST criteria 50 Scale cognitive subscale 50 ACTEMRA 50 p ≤ 50 anagrelide 50 BENICAR 50 INCB# [003] 50 pCR 50 clinically meaningful improvement 50 idraparinux 50 pain palliation 50 Minority Cancer Awareness 50 LANTUS ® 50 moderate hepatic insufficiency 50 Showed Significant 50 Ankylosing Spondylitis 50 Adverse events 50 BoNTA 50 serum leptin 50 recurrent venous thromboembolism 50 serum clusterin levels 50 Sprycel dasatinib 50 sirolimus eluting stent 50 UPDRS motor 50 Stent thrombosis 50 CDAI 50 STELARA 50 Maisie McCabe Media 50 glycoprotein IIb IIIa inhibitors 50 migalastat HCl 50 nonfatal MI 50 3TC lamivudine Epivir 50 ezetimibe simvastatin 50 Fungal Infections 50 vandetanib 50 hypoglycemic events 50 #q# deletion syndrome 50 administered subcutaneously 50 ONGLYZA 50 affective psychosis 50 peg interferon 50 eosinophilic asthma 50 recurrent ischemia 50 DAS# [002] 50 -#.# ± [002] 50 Combo Therapy 50 mg Androxal 50 zoledronic acid Reclast 50 #.#-#.# p = 50 MACCE 50 allogeneic SCT 50 mg tid 50 oral ridaforolimus 50 recurrent DVT 50 fondaparinux 50 Foot Ankle 50 Elitek 50 standard chemotherapy regimen 50 nilotinib 50 induction regimen 50 divalproex sodium 50 Health Aff Millwood 50 captopril 50 repeat revascularization 50 COPD exacerbation 50 aspartate aminotransferase AST 50 urine albumin 50 RoACTEMRA 50 carboplatin paclitaxel 50 highly emetogenic 50 metastatic malignant melanoma 50 refractory AML 50 epoetin alpha 50 Reduces Mortality 50 #mg BID [002] 50 MACUGEN 50 advanced adenoma 50 response CCyR 50 cGy 50 glycosylated hemoglobin 50 SGRQ 50 dacarbazine chemotherapy 50 prior relapsers 50 mmol l 50 HCV RESPOND 2 50 virologic responses 50 % CI #.#-#.# [002] 50 Kaplan Meier estimates 50 ONGLYZA TM 50 ADAS Cog 50 fluvastatin 50 peg IFN 50 scores TNSS 50 postintervention 50 Virologic 50 1mg 2mg 50 enoxaparin 50 Gentle Path compound 50 unfractionated heparin 50 zoledronate 50 visilizumab 50 mTSS 50 TPV r 50 neutrophil counts 50 subtrochanteric 50 lamivudine 50 β blockers 50 doxorubicin docetaxel 50 ARICEPT 50 PROMACTA 50 Psychiatric Services #:#-#,# 50 subcutaneous insulin 50 #mg/m# [001] 50 EDSS scores 50 OADs 50 ECOG PS 50 Psychiatry Clin Neurosci 50 macroalbuminuria 50 patients evaluable 50 composite endpoint 50 dose atorvastatin 50 fasting plasma glucose 50 pentoxifylline 50 herpetic keratitis 50 Melissa Lampman Kamloops 50 Paxil paroxetine 50 WOMAC pain 50 tiotropium bromide 50 heavily pretreated 50 undetectable viral load 50 extrapyramidal symptoms 50 Major Adverse Cardiac 50 advanced adenomas 50 -5 -6 50 target vessel revascularization 50 #:#-#,# [002] 50 gemifloxacin 50 μmol L 50 Uterine Cancer 50 abiraterone acetate 50 underwent resection 50 pegylated interferon 50 follicular lymphomas 50 NFL -Kenya Samburu 50 gemcitabine carboplatin 50 KAPVAY 50 By BRIAN ROKOS 50 UPDRS 50 Risedronate 50 cerebrovascular accident 50 virologic breakthrough 50 #-#,# mg 49 CVD mortality 49 StockProfit.com Chart 49 mapatumumab 49 liver histology 49 nucleoside naive patients 49 viral kinetics 49 Liver Failure 49 achieving PASI 49 lymphocytosis 49 cardiovascular hospitalizations 49 ethambutol 49 lipid parameters 49 CI #.#-#.# [001] 49 HBeAg positive 49 PCWP 49 NEVO ™ 49 Alzheimer Disease Assessment 49 olmesartan 49 μg kg 49 ibandronate 49 evaluable 49 abatacept 49 multivariate adjustment 49 nodular partial response 49 MAGE A3 ASCI 49 dose regimens 49 candesartan cilexetil 49 Fibromyalgia Impact Questionnaire 49 risperidone Risperdal 49 infusional 5-FU/LV 49 REVIVE Diabetes 49 FEDERAL INSPECTION Mon 49 pulmonary exacerbation 49 postoperative AF 49 oral FTY# 49 partial remissions 49 VaD 49 nonsignificant 49 g dL 49 pioglitazone 49 MIRAPEX 49 periprocedural 49 p = .# [002] 49 AGILECT R 49 clopidogrel Plavix 49 Secondary endpoints 49 Orthostatic Hypotension 49 pulmonary capillary wedge 49 transaminases 49 Lung Cancer Survival 49 Mania Rating Scale 49 CC genotype 49 goserelin 49 confidence intervals CIs 49 antiemetics 49 Colorectal Cancers 49 CLL SLL 49 GAMMAGARD 49 valsartan 49 briakinumab 49 Acute Stroke 49 tolvaptan 49 #ug [001] 49 mg/m2 dose 49 prior chemotherapy regimens 49 Animation Trivia Quiz 49 gastric pH 49 glycated hemoglobin HbA1c 49 pamidronate 49 nonoperative 49 Adalimumab 49 INVEGA ® 49 phonophobia 49 pyrazinamide 49 lymphopenia 49 dexamethasone Decadron 49 NYHA functional class